JPRN-UMIN000031155已完成未知
Efficacy and feasibility of re-irradiation with CyberKnife radiosurgery and stereotactic radiotherapy as a salvage treatment for in-field neck lymph node recurrences after conventional radiotherapy: a retrospective study - Efficacy and feasibility of re-irradiation with CyberKnife radiosurgery and stereotactic radiotherapy as a salvage treatment for in-field neck lymph node recurrences after conventional radiotherapy: a retrospective study
Kanto Neurosurgical Hospital0 个研究点目标入组 16 人开始时间: 2018年3月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
The one-year local control (LC) and overall survival rates were 81% and 71%, respectively.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •recurrences out-field radiotherapy
研究者
相似试验
已完成
不适用
Concurrent Chemoradiotherapy with Cisplatin and Docetaxel for Advanced Head and Neck Cancer Multicentric Phase II StudyHead and neck squamous cell carcinoma at stage III and IVJPRN-C000000306Department of Otorhinolaryngology and Head and Neck Surgery, Osaka University School of Medicine150
已完成
不适用
A retrospective observational study for elderly patients with uterine cervical cancer using image guided brachytherapyuterine cervical cancerJPRN-UMIN000027888Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Sciences and Technology105
已完成
不适用
Cross-sectional study of the effectiveness and safety of proton beam therapy for liver metastatic 3 or less lesions in gastric cancer patients without extrahepatic lesioGastric cancerJPRN-UMIN000041791Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University7
已完成
不适用
Randomized contorol trial of transarterial chemoinfusion with cisplatin-lipiodol susupension or miriplatin-lipiodol suspension for advanced HCCHepatocellular carcinomaJPRN-UMIN000003452First Department of Internal Medicine,Gifu University Hospital98
已完成
2 期
Phase 2 study evaluating the efficacy and safety of the combination of Bendamustine, Rituximab and Dexamethazone (RBenda-D) for treatment of CD20-positive relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.JPRN-UMIN000008145Kyoto Prefectural University of Medicine/K-LSG33